FDA accepts Roche Tecentriq sBLA
Analysis based on 8 articles · First reported Jun 11, 2026 · Last updated Jun 11, 2026
The acceptance of Roche>>>'s sBLA for Atezolizumab>>> with Priority Review by the United States — Food and Drug Administration>>> is a positive development for Roche>>>'s stock, as it signals potential market expansion for its oncology portfolio. If approved, Atezolizumab>>> could become a new standard of care for stage III colon cancer, leading to increased revenue for Roche>>> and impacting the pharmaceutical and biotechnology industries.
Roche>>> announced that the United States — Food and Drug Administration>>> has accepted its supplemental Biologics License Application (sBLA) for adjuvant Atezolizumab>>> and Atezolizumab Hybreza in combination with chemotherapy for stage III deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) colon cancer. The United States — Food and Drug Administration>>> granted Priority Review, with a decision expected by October 9, 2026. This filing is based on the phase III ATOMIC study, which showed that Atezolizumab>>> plus chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone. This development could establish Atezolizumab>>> as a new standard of care, addressing the critical need for new adjuvant treatment options for colon cancer patients, as nearly one in three relapse within five years.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard